Integra LifeSciences (NASDAQ:IART) Reaches New 1-Year Low at $24.16

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $24.16 and last traded at $25.06, with a volume of 600287 shares trading hands. The stock had previously closed at $28.89.

Wall Street Analyst Weigh In

A number of analysts recently commented on IART shares. Truist Financial lowered their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. JMP Securities reduced their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Finally, Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Stock Performance

The stock’s 50 day moving average is $33.75 and its 200 day moving average is $38.44. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of 34.81, a PEG ratio of 0.87 and a beta of 1.17. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The firm had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the business posted $0.94 EPS. On average, analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Capital Research Global Investors boosted its holdings in shares of Integra LifeSciences by 40.1% in the fourth quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock worth $187,149,000 after buying an additional 1,228,996 shares during the period. Deerfield Management Company L.P. Series C bought a new position in shares of Integra LifeSciences in the third quarter valued at approximately $43,034,000. Norges Bank bought a new position in shares of Integra LifeSciences in the fourth quarter worth about $29,272,000. Assenagon Asset Management S.A. acquired a new position in shares of Integra LifeSciences during the third quarter valued at about $25,443,000. Finally, Point72 Europe London LLP boosted its stake in Integra LifeSciences by 54.9% during the fourth quarter. Point72 Europe London LLP now owns 719,663 shares of the life sciences company’s stock worth $31,341,000 after buying an additional 255,201 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.